Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M4QM
|
||||
| Former ID |
DIB019688
|
||||
| Drug Name |
d(CH2)5[Tyr(Me)2]AVP
|
||||
| Synonyms |
Pmp[Tyr(Me)2]AVP; SKF-100273; d(CH2)5[O-methyl-Tyr2]AVP
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C52H74N14O12S2
|
||||
| InChI |
InChI=1S/C52H74N14O12S2/c1-78-32-16-14-31(15-17-32)25-35-46(73)63-36(24-30-10-4-2-5-11-30)47(74)61-34(18-19-40(53)67)45(72)64-37(26-41(54)68)48(75)65-38(29-79-80-52(27-43(70)60-35)20-6-3-7-21-52)50(77)66-23-9-13-39(66)49(76)62-33(12-8-22-58-51(56)57)44(71)59-28-42(55)69/h2,4-5,10-11,14-17,33-39H,3,6-9,12-13,18-29H2,1H3,(H2,53,67)(H2,54,68)(H2,55,69)(H,59,71)(H,60,70)(H,61,74)(H,62,76)(H,63,73)(H,64,72)(H,65,75)(H4,56,57,58)/t33-,34-,35+,36-,37-,38-,39+/m0/s1
|
||||
| InChIKey |
QVQOGNOOAMQKCE-OVSZNHMYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Vasopressin V2 receptor | Target Info | Antagonist | [2] | |
| Vasopressin V1b receptor | Target Info | Antagonist | [3] | ||
| Oxytocin receptor | Target Info | Antagonist | [4] | ||
| Vasopressin V1a receptor | Target Info | Antagonist | [5] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Vasopressin-regulated water reabsorptionhsa04020:Calcium signaling pathway | |||||
| Vascular smooth muscle contractionhsa04020:Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Oxytocin signaling pathwayhsa04020:Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Oxytocin receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| PathWhiz Pathway | Vasopressin Regulation of Water Homeostasis | ||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (s) signalling events | |||||
| Vasopressin regulates renal water homeostasis via AquaporinsR-HSA-388479:Vasopressin-like receptors | |||||
| G alpha (q) signalling eventsR-HSA-388479:Vasopressin-like receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Regulation of Water Balance by Renal Aquaporins | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Oxytocin signaling | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2223). | ||||
| REF 2 | Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22. | ||||
| REF 3 | 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol. 1997 Jun 1;53(11):1711-7. | ||||
| REF 4 | Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. | ||||
| REF 5 | Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur J Biochem. 2000 Jul;267(13):4253-63. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.